---
title: "LifeMD | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 47.28 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295008627.md"
datetime: "2026-08-05T20:17:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295008627.md)
  - [en](https://longbridge.com/en/news/295008627.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295008627.md)
generator: "portal-rs"
---

# LifeMD | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 47.28 M

Revenue: As of FY2026 Q2, the actual value is USD 47.28 M, missing the estimate of USD 49.1 M.

EPS: As of FY2026 Q2, the actual value is USD -0.16.

EBIT: As of FY2026 Q2, the actual value is USD -7.084 M.

### Second Quarter 2026 Financial Highlights

#### Overall Performance

-   **Revenue**: LifeMD, Inc. reported total revenue of $47.3 million for the second quarter of 2026, which was within the company’s guidance range of $47 million to $50 million. This represents a -4% decrease compared to $49.0 million in the prior-year period. Approximately 84% of this revenue was derived from recurring subscriptions.
-   **Adjusted EBITDA**: The adjusted EBITDA loss was approximately - $3.5 million, an improvement of approximately 21% sequentially. This compares to an adjusted EBITDA of approximately $3.9 million in the prior-year period, marking a -191% year-over-year change.

#### Operational Metrics

-   **Gross Profit**: Gross profit was $42.0 million, remaining essentially flat compared to $42.2 million in the prior-year period despite lower revenue.
-   **Gross Margin**: Gross margin expanded to approximately 89% in Q2 2026, an increase of approximately 280 basis points from 86% in Q2 2025.
-   **Operating Loss from Continuing Operations**: The operating loss from continuing operations was - $7,129,601 for Q2 2026, compared to - $2,346,886 for Q2 2025.
-   **Selling and Marketing Expenses**: These expenses increased 27% year-over-year to $28.0 million but declined $1.8 million from the first quarter of 2026.
-   **General and Administrative Expenses**: These expenses declined 5% to $13.6 million.
-   **GAAP Net Loss from Continuing Operations Attributable to Common Stockholders**: The GAAP net loss from continuing operations attributable to common stockholders was - $7.9 million, or - $0.16 per share, for Q2 2026, compared to a GAAP net loss of - $3.8 million, or - $0.09 per share, in the prior-year period.

#### Cash Position

-   **Cash Balance**: LifeMD, Inc. exited the quarter with $25.1 million in cash as of June 30, 2026, and reported no debt.
-   **Liquidity**: The company had an undrawn $30 million revolving credit facility, providing additional liquidity.
-   **Net Cash Used in Operating Activities (Continuing Operations)**: Net cash used in operating activities from continuing operations was - $6,925,648 for Q2 2026, compared to $6,101,609 provided in Q2 2025.
-   **Net Cash Used in Investing Activities (Continuing Operations)**: Net cash used in investing activities from continuing operations was - $1,634,312 for Q2 2026, compared to - $2,836,983 for Q2 2025.
-   **Net Cash Used in Financing Activities (Continuing Operations)**: Net cash used in financing activities from continuing operations was - $776,562 for Q2 2026, compared to - $2,828,850 for Q2 2025.

#### Key Performance Indicators (KPIs)

-   **Total Active Subscribers**: Total active subscribers increased 20% year-over-year to approximately 356,000 at quarter end.
-   **Weight Management Program Subscribers**: The number of Weight Management Program subscribers grew to approximately 108,000 at quarter end, up from just under 100,000 at the end of the first quarter of 2026.
-   **GLP-1 Therapies**: Approximately 95% of new weight management patients are now starting treatment with branded GLP-1 therapies.

#### Outlook and Guidance

LifeMD, Inc. expects a return to positive adjusted EBITDA in the second half of 2026 and projects a fourth-quarter exit revenue run rate of approximately $250 million annually with approximately $22 million of annualized adjusted EBITDA. For the full year 2026, the company revised its revenue guidance to a range of $205.5 million to $212.5 million and adjusted EBITDA guidance to - $6.0 million to breakeven, including launch costs for XYOSTED®. For the third quarter of 2026, revenue is expected to be in the range of $48 million to $51 million, with adjusted EBITDA in the range of - $1 million to positive $2 million.

### Related Stocks

- [LFMD.US](https://longbridge.com/en/quote/LFMD.US.md)

## Related News & Research

- [LifeMD Reports Second Quarter 2026 Results | LFMD Stock News](https://longbridge.com/en/news/295008118.md)
- [LifeMD Q2 2026 earnings: GLP-1 transition widens losses despite margin gains](https://longbridge.com/en/news/295031758.md)
- [B. Riley Financial Begins Coverage on LifeMD (NASDAQ:LFMD)](https://longbridge.com/en/news/298743624.md)
- [LifeMD Earnings Call: Growth Surges, Profits Deferred](https://longbridge.com/en/news/285647524.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**